fingolimod hydrochloride has been researched along with Habermann Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Maiberger, M; Maloni, H; Mukharesh, L; Wallin, M | 1 |
1 other study(ies) available for fingolimod hydrochloride and Habermann Disease
| Article | Year |
|---|---|
Unusual adverse dermatologic conditions associated with fingolimod and natalizumab in a patient with relapsing remitting multiple sclerosis.
Topics: Adult; Drug Eruptions; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Pityriasis Lichenoides; Vasculitis, Leukocytoclastic, Cutaneous | 2020 |